Loading data for PBIGF — first visit, this takes a few seconds.

Paradigm Biopharmaceuticals Limited

PBIGF · OTC Markets OTCPK · USD

0.19 -0.01 (-5.00%)

收盤價： Sep 15, 2026, 8:00 PM

市值: $125.2M
成交量: 25K
股息殖利率: n/a
下次財報日期: n/a

內在價值

正在載入內在價值…

分析師預測

股票預測 →

分析師預測無法取得

12個月目標價 · n/a 位分析師

分析師共識： n/a

正在載入K線和訊號…

財務表現

查看財務 →

營收 (ttm): —
淨利（ttm）: -$56.33M

正在載入...

最新財報

n/a

	已通報	較預期	YoY 變更
營收	—	n/a	n/a
EPS	—	n/a	n/a

下次財報

n/a

查看財報詳情 →

指標

買價: 0.16
市值: 125M
營收 (ttm): n/a
淨利（ttm）: -56.3M
: 0.02
: -0.11
: n/a
: n/a
P/B (ttm): 46.58
P/S (ttm): n/a
財報日期: n/a
賣價: 0.2
成交量: 25,000
20 日平均成交量: 10,470
開盤價: 0.18
前收盤價: 0.20
當日區間: 0.18 - 0.18
52 週範圍: 0.10 - 0.35
分析師: n/a
目標價: n/a
股利: n/a
除息日: n/a

新聞動態

Market Sentiment Around Loss-Making Paradigm Biopharmaceuticals Limited (ASX:PAR)

Simply Wall St.3 月前

Could Paradigm Biopharmaceuticals’ (ASX:PAR) Leadership Presence Signal a Shift in Its Growth Story?

Simply Wall St.10 月前

Paradigm Biopharmaceuticals (ASX:PAR): Exploring Valuation as Leadership Prepares for Ignite Investment Summit Presentation

Simply Wall St.10 月前

Weekly Picks: 🇺🇸 A Hedge Against US Government Shutdown And 2 More Picks

Simply Wall St.11 月前

Paradigm Biopharmaceuticals Limited's (ASX:PAR) Profit Outlook

Simply Wall St.11 月前

關於 Paradigm Biopharmaceuticals Limited

查看公司資料 →

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia. Biotechnology · Healthcare

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

產業 Biotechnology

類股 Healthcare

IPO 日期 May 10, 2019

員工 n/a

證券交易所 OTC Markets OTCPK

股票代號 PBIGF

網站 https://www.paradigmbiopharma.com